Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 47
Filtrar
1.
Behav Brain Res ; 385: 112561, 2020 05 15.
Artigo em Inglês | MEDLINE | ID: mdl-32070690

RESUMO

BACKGROUND: As an atypical antipsychotic drug, quetiapine had been approved for bipolar disorder and for adjunctive therapy in major depressive disorder and schizophrenia. Recently quetiapine has been suggested to be a promising pharmacotherapy for alcohol dependence. This study was performed to determine the effects of quetiapine in rats chronically exposed to ethanol. METHODS: Rats were exposed to ethanol solution (10 %; v/v) for 6 weeks. Saline or one of three doses of quetiapine (10, 20 or 40 mg/kg/day) was given by oral gavage while ethanol exposure for the next 14 weeks. Performance of learning and memory and withdrawal signs were evaluated. Then immunohistochemistry, western blot, quantitative real-time-PCR and transmission electron microscopy were performed to determine the effects of quetiapine on alterations of brain white matter markers (myelin basic protein, MBP; proteolipid protein, PLP) and morphology caused by chronic ethanol exposure. RESULTS: Quetiapine treatment significantly alleviated withdrawal signs in the ethanol exposed rats. Chronic ethanol exposure reduced Y-type electric maze scores and the protein/mRNA expression levels of MBP and PLP in the prefrontal cortex and hippocampus, and these effects were reversed by quetiapine treatment. Similar ultrastructure morphological changes were observed. CONCLUSIONS: Chronic quetiapine treatment alleviated the damage induced by chronic ethanol exposure with regard to learning and memory ability and to brain white matter. Thus, quetiapine appears to be a potentially promising pharmacotherapy for the treatment of alcohol use disorder.


Assuntos
Alcoolismo/fisiopatologia , Antipsicóticos/farmacologia , Comportamento Animal/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Memória/efeitos dos fármacos , Proteína Básica da Mielina/efeitos dos fármacos , Proteína Proteolipídica de Mielina/efeitos dos fármacos , Fumarato de Quetiapina/farmacologia , Alcoolismo/genética , Alcoolismo/metabolismo , Animais , Encéfalo/metabolismo , Encéfalo/ultraestrutura , Depressores do Sistema Nervoso Central/efeitos adversos , Etanol/efeitos adversos , Aprendizagem/efeitos dos fármacos , Microscopia Eletrônica de Transmissão , Proteína Básica da Mielina/genética , Proteína Básica da Mielina/metabolismo , Proteína Proteolipídica de Mielina/genética , Proteína Proteolipídica de Mielina/metabolismo , RNA Mensageiro/efeitos dos fármacos , RNA Mensageiro/metabolismo , Ratos , Síndrome de Abstinência a Substâncias/etiologia , Síndrome de Abstinência a Substâncias/fisiopatologia
2.
Nan Fang Yi Ke Da Xue Xue Bao ; 38(9): 1115-1120, 2018 Aug 30.
Artigo em Chinês | MEDLINE | ID: mdl-30377113

RESUMO

OBJECTIVE: To investigate the mechanism underlying propofol- induced down-regulation of myelin basic protein (MBP) in zebrafish embryos. METHODS: Zebrafish embryos (6-48 h post-fertilization [hpf]) were randomized into 4 equal groups for exposure to dimethyl sulfoxide (DMSO), 20 µg/mL propofol, 30 µg/mL propofol, or no particular treatment (control group). The larvae were collected at 48 or 72 hpf for detecting the mRNA levels of MBP, Olig1, Olig2, and Sox10 using qRT-PCR (n=80). The protein expression of MBP was quantitatively detected using Western blotting (n=80), and the apoptosis of the oligodendrocytes was investigated using TUNEL staining (n=6). RESULTS: Exposure to 20 and 30 µg/mL propofol caused significant reductions in the mRNA expressions of Olig1, Olig2, and Sox10 at 48 and 72 hpf (P < 0.05) and also in MBP mRNA and protein levels at 72 hpf (P < 0.05). Exposure to 30 µg/mL propofol induced more obvious reduction in MBP protein expression than 20 µg/mL propofol at 72 hpf (P < 0.05), and the exposures resulted in a significant increase of oligodendrocyte apoptosis at 72 hpf (P < 0.05). CONCLUSIONS: Propofol exposure reduces MBP expression at both the mRNA and protein levels in zebrafish embryos by down-regulating the expressions of Olig1, Olig2 and Sox10 mRNA levels and increasing apoptosis of the oligodendrocytes.


Assuntos
Proteína Básica da Mielina/efeitos dos fármacos , Oligodendroglia/efeitos dos fármacos , Propofol/farmacologia , Animais , Apoptose , Regulação para Baixo , Embrião não Mamífero , Proteína Básica da Mielina/metabolismo , Fator de Transcrição 2 de Oligodendrócitos/metabolismo , Oligodendroglia/citologia , RNA Mensageiro/metabolismo , Distribuição Aleatória , Fatores de Transcrição SOXE/metabolismo , Fatores de Transcrição/metabolismo , Peixe-Zebra/embriologia , Proteínas de Peixe-Zebra/metabolismo
3.
Stroke ; 49(5): 1257-1266, 2018 05.
Artigo em Inglês | MEDLINE | ID: mdl-29636425

RESUMO

BACKGROUND AND PURPOSE: Cognitive impairment is a common outcome for stroke survivors. Growth hormone (GH) could represent a potential therapeutic option as this peptide hormone has been shown to improve cognition in various clinical conditions. In this study, we evaluated the effects of peripheral administration of GH at 48 hours poststroke for 28 days on cognitive function and the underlying mechanisms. METHODS: Experimental stroke was induced by photothrombotic occlusion in young adult mice. We assessed the associative memory cognitive domain using mouse touchscreen platform for paired-associate learning task. We also evaluated neural tissue loss, neurotrophic factors, and markers of neuroplasticity and cerebrovascular remodeling using biochemical and histology analyses. RESULTS: Our results show that GH-treated stroked mice made a significant improvement on the paired-associate learning task relative to non-GH-treated mice at the end of the study. Furthermore, we observed reduction of neural tissue loss in GH-treated stroked mice. We identified that GH treatment resulted in significantly higher levels of neurotrophic factors (IGF-1 [insulin-like growth factor-1] and VEGF [vascular endothelial growth factor]) in both the circulatory and peri-infarct regions. GH treatment in stroked mice not only promoted protein levels and density of presynaptic marker (SYN-1 [synapsin-1]) and marker of myelination (MBP [myelin basic protein]) but also increased the density and area coverage of 2 major vasculature markers (CD31 and collagen-IV), within the peri-infarct region. CONCLUSIONS: These findings provide compelling preclinical evidence for the usage of GH as a potential therapeutic tool in the recovery phase of patients after stroke.


Assuntos
Aprendizagem por Associação/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Cognição/efeitos dos fármacos , Hormônio do Crescimento/farmacologia , Acidente Vascular Cerebral/metabolismo , Animais , Encéfalo/metabolismo , Encéfalo/patologia , Circulação Cerebrovascular , Colágeno Tipo IV/efeitos dos fármacos , Colágeno Tipo IV/metabolismo , Fator de Crescimento Insulin-Like I/efeitos dos fármacos , Fator de Crescimento Insulin-Like I/metabolismo , Masculino , Camundongos , Proteína Básica da Mielina/efeitos dos fármacos , Proteína Básica da Mielina/metabolismo , Plasticidade Neuronal/efeitos dos fármacos , Molécula-1 de Adesão Celular Endotelial a Plaquetas/efeitos dos fármacos , Molécula-1 de Adesão Celular Endotelial a Plaquetas/metabolismo , Distribuição Aleatória , Acidente Vascular Cerebral/patologia , Sinapsinas/efeitos dos fármacos , Sinapsinas/metabolismo , Fator A de Crescimento do Endotélio Vascular/efeitos dos fármacos , Fator A de Crescimento do Endotélio Vascular/metabolismo , Remodelação Vascular/efeitos dos fármacos , Aumento de Peso/efeitos dos fármacos
4.
Stroke ; 47(2): 542-7, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26670084

RESUMO

BACKGROUND AND PURPOSE: Chronic cerebral hypoperfusion can lead to ischemic white matter injury resulting in vascular dementia. To characterize white matter injury in vascular dementia, we investigated disintegration of diverse white matter components using a rat model of chronic cerebral hypoperfusion. METHODS: Chronic cerebral hypoperfusion was modeled in Wistar rats by permanent occlusion of the bilateral common carotid arteries. We performed cognitive behavioral tests, including the water maze task, odor discrimination task, and novel object test; histological investigation of neuroinflammation, oligodendrocytes, myelin basic protein, and nodal or paranodal proteins at the nodes of Ranvier; and serial diffusion tensor imaging. Cilostazol was administered to protect against white matter injury. RESULTS: Diverse cognitive impairments were induced by chronic cerebral hypoperfusion. Disintegration of white matter was characterized by neuroinflammation, loss of oligodendrocytes, attenuation of myelin density, structural derangement at the nodes of Ranvier, and disintegration of white matter tracts. Cilostazol protected against cognitive impairments and white matter disintegration. CONCLUSIONS: White matter injury induced by chronic cerebral hypoperfusion can be characterized by disintegration of diverse white matter components. Cilostazol might be a therapeutic strategy against white matter disintegration in patients with vascular dementia.


Assuntos
Isquemia Encefálica/patologia , Estenose das Carótidas/patologia , Demência Vascular/patologia , Hipocampo/patologia , Leucoencefalopatias/patologia , Substância Branca/patologia , Animais , Comportamento Animal/efeitos dos fármacos , Isquemia Encefálica/etiologia , Isquemia Encefálica/metabolismo , Estenose das Carótidas/complicações , Estenose das Carótidas/metabolismo , Doença Crônica , Cilostazol , Cognição/efeitos dos fármacos , Demência Vascular/etiologia , Demência Vascular/metabolismo , Imagem de Tensor de Difusão , Modelos Animais de Doenças , Hipocampo/efeitos dos fármacos , Hipocampo/metabolismo , Inflamação , Leucoencefalopatias/etiologia , Leucoencefalopatias/metabolismo , Proteína Básica da Mielina/efeitos dos fármacos , Proteína Básica da Mielina/metabolismo , Fármacos Neuroprotetores/farmacologia , Testes Neuropsicológicos , Oligodendroglia/efeitos dos fármacos , Oligodendroglia/metabolismo , Oligodendroglia/patologia , Nós Neurofibrosos/efeitos dos fármacos , Nós Neurofibrosos/metabolismo , Nós Neurofibrosos/patologia , Ratos , Ratos Wistar , Tetrazóis/farmacologia , Substância Branca/efeitos dos fármacos , Substância Branca/metabolismo
5.
Acta Neurochir Suppl ; 121: 199-202, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26463948

RESUMO

Intracerebral hemorrhage (ICH)-induced white matter injury has not been well studied. The objective of this study was to examine the effect of zinc protoporphyrin (ZnPP) on white matter injury induced by ICH. This study was divided into two parts. In the first part, rats received either a needle insertion (sham) or 100 µl autologous blood into the right basal ganglia. The rats were euthanized at 1, 3, 7, 14, or 28 days later for myelin basic protein (MBP) measurement. In the second part, rats had intracerebral infusion of 100 µl autologous blood, and an intraperitoneal osmotic mini-pump was implanted immediately after ICH to deliver vehicle or ZnPP (1 nmol/h), a heme oxygenase inhibitor, for up to 14 days. Rats were euthanized at day 28 for MBP staining. The number of MBP-labeled fiber bundles and their area were determined. The time-course showed that the white matter was lost in the ipsilateral basal ganglia from day 1 to day 28 after ICH. The number of MBP-labeled bundles and their area were significantly lower 2 weeks after ICH compared with sham-operated rats (p < 0.05). Systemic treatment with ZnPP attenuated the loss of MBP-labeled bundles (p < 0.01) and area (p < 0.01). In conclusion, marked white matter injury occurs after ICH. ZnPP reduces white matter injury, suggesting a role of heme degradation products in ICH-induced white matter damage.


Assuntos
Hemorragia Cerebral/metabolismo , Inibidores Enzimáticos/farmacologia , Proteína Básica da Mielina/efeitos dos fármacos , Protoporfirinas/farmacologia , Substância Branca/efeitos dos fármacos , Animais , Heme Oxigenase (Desciclizante)/antagonistas & inibidores , Imuno-Histoquímica , Masculino , Proteína Básica da Mielina/metabolismo , Ratos , Ratos Sprague-Dawley , Substância Branca/metabolismo , Substância Branca/patologia
6.
Stroke ; 46(1): 221-8, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25395417

RESUMO

BACKGROUND AND PURPOSE: Translational research is beginning to reveal the importance of trophic factors as a therapy for cellular brain repair. The purpose of this study was to analyze whether brain-derived neurotrophic factor (BDNF) administration could mediate oligodendrogenesis and remyelination after white matter injury in subcortical stroke. METHODS: Ischemia was induced in rats by injection of endothelin-1. At 24 hours, 0.4 µg/kg of BDNF or saline was intravenously administered to the treatment and control groups, respectively. Functional evaluation, MRI, and fiber tract integrity on tractography images were analyzed. Proliferation (KI-67) and white matter repair markers (A2B5, 2',3'-cyclic-nucleotide 3'-phosphodiesterase [CNPase], adenomatous polyposis coli [APC], platelet-derived growth factor receptor alpha [PDGFR-α], oligodendrocyte marker O4 [O4], oligodendrocyte transcription factor [Olig-2], and myelin basic protein [MBP]) were analyzed at 7 and 28 days. RESULTS: The BDNF-treated animals showed less functional deficit at 28 days after treatment than the controls (P<0.05). Although T2-MRI did not show differences in lesion size at 7 and 28 days between groups, diffusion tensor imaging tractography analysis revealed significantly better tract connectivity at 28 days in the BDNF group than in the controls (P<0.05). Increased proliferation of oligodendrocyte progenitors was observed in treated animals at 7 days (P<0.05). Finally, the levels of white matter repair markers (A2B5, CNPase, and O4 at 7 days; Olig-2 and MBP at 28 days) were higher in the BDNF group than in the controls (P<0.05). CONCLUSIONS: BDNF administration exerted better functional outcome, oligodendrogenesis, remyelination, and fiber connectivity than controls in rats subjected to subcortical damage in ischemic stroke.


Assuntos
Isquemia Encefálica/patologia , Fator Neurotrófico Derivado do Encéfalo/farmacologia , Diferenciação Celular/efeitos dos fármacos , Bainha de Mielina/efeitos dos fármacos , Oligodendroglia/efeitos dos fármacos , Acidente Vascular Cerebral/patologia , Substância Branca/efeitos dos fármacos , 2',3'-Nucleotídeo Cíclico Fosfodiesterases/efeitos dos fármacos , Proteína da Polipose Adenomatosa do Colo/efeitos dos fármacos , Animais , Fatores de Transcrição Hélice-Alça-Hélice Básicos/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Isquemia Encefálica/complicações , Imagem de Tensor de Difusão , Imageamento por Ressonância Magnética , Proteína Básica da Mielina/efeitos dos fármacos , Bainha de Mielina/patologia , Bainha de Mielina/fisiologia , Ratos , Receptor alfa de Fator de Crescimento Derivado de Plaquetas/efeitos dos fármacos , Acidente Vascular Cerebral/etiologia , Substância Branca/patologia
7.
Neurosci Bull ; 29(2): 155-64, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23456566

RESUMO

Axonal myelination is an essential process for normal functioning of the vertebrate central nervous system. Proper formation of myelin sheaths around axons depends on the timely differentiation of oligodendrocytes. This differentiation occurs on a predictable schedule both in culture and during development. However, the timing mechanisms for oligodendrocyte differentiation during normal development have not been fully uncovered. Recent studies have identified a large number of regulatory factors, including cell-intrinsic factors and extracellular signals, that could control the timing of oligodendrocyte differentiation. Here we provide a mechanistic and critical review of the timing control of oligodendrocyte differentiation.


Assuntos
Diferenciação Celular/fisiologia , Sistema Nervoso Central , Oligodendroglia/fisiologia , Animais , Axônios/fisiologia , Sistema Nervoso Central/citologia , Sistema Nervoso Central/fisiologia , Humanos , Proteína Básica da Mielina/efeitos dos fármacos , Proteína Básica da Mielina/metabolismo , Bainha de Mielina/fisiologia , Fatores de Tempo
8.
J Occup Health ; 55(1): 29-38, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23183024

RESUMO

OBJECTIVES: Human cases of 1-bromopropane (1-BP) toxicity showed ataxic gait and cognitive dysfunction, whereas rat studies showed pyknotic shrinkage in cerebellar Purkinje cells and electrophysiological changes in the hippocampus. The present study investigated the effects of 1-BP on astrocytes and oligodendrocytes in the rat cerebellum and hippocampus to find sensitive markers of central nervous system toxicity. METHODS: Forty-eight F344 rats were divided into four equal groups and exposed to 1-BP at 0, 400, 800 and 1,000 ppm for 8 h/day; 7 days/week, for 4 weeks. Nine and three rats per group were used for biochemical and histopathological studies, respectively. RESULTS: Kluver-Barrera staining showed pyknotic shrinkage in the cytoplasm of Purkinje cells and nuclei of granular cells in the cerebellum at 1,000 ppm. Immunohistochemical analysis showed increased length of glial fibrillary acidic protein (GFAP)-positive processes of astrocytes in the cerebellum, hippocampus and dentate gyrus at 800 and 1,000 ppm. The myelin basic protein (MBP) level was lower at 1,000 ppm. The numbers of astrocytes and granular cells per tissue volume increased at 400 ppm or higher. CONCLUSION: The present study showed that elongation of processes of astrocytes accompanies degeneration of granular cells and Purkinje cells in the cerebellum of the rats exposed to 1-BP. The decrease in MBP and number of oligodendrocytes suggest adverse effects on myelination. The increase in astrocyte population per tissue volume in the cerebellum might be a sensitive marker of 1-BP neurotoxicity, but the underlying mechanism for this change remains elusive.


Assuntos
Astrócitos/efeitos dos fármacos , Cerebelo/efeitos dos fármacos , Hipocampo/efeitos dos fármacos , Oligodendroglia/efeitos dos fármacos , Animais , Relação Dose-Resposta a Droga , Ensaio de Imunoadsorção Enzimática , Hidrocarbonetos Bromados/toxicidade , Masculino , Proteína Básica da Mielina/efeitos dos fármacos , Células de Purkinje/efeitos dos fármacos , RNA Mensageiro , Ratos , Ratos Endogâmicos F344
9.
Ann Nutr Metab ; 56(2): 83-90, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20090312

RESUMO

BACKGROUND/AIMS: This study investigated the effects of dietary folic acid on the expression of myelin basic protein (MBP) in the maternal brain and spinal cord during pregnancy and lactation. METHODS: Female Sprague-Dawley rats were fed either a folic-acid-supplemented diet (FS, 8 mg/kg diet) or a folic-acid-deficient diet (FD, 0 mg/kg diet) from 2 weeks prior to mating until the end of lactation. The expressions of MBP were analyzed using Western blot analysis and immunohistochemistry, and myelin oligodendrocyte glycoprotein (MOG), and neuronal nuclear antigen by immunohistochemistry. RESULTS: The cerebrocortical expression of MBP was 87% higher at day 20 of pregnancy than before pregnancy in FS animals (p < 0.05) but did not change significantly in FD animals. No significant change was observed in the hippocampus or spinal cord in either dietary treatment group. The cerebrocortical MOG and NeuN expressions were significantly lower in FD animals than in FS animals before pregnancy and increased at day 20 of pregnancy but did not differ with the dietary folic acid level. CONCLUSIONS: Folic acid deficiency did not increase the expression level of MBP in the cerebral cortex during pregnancy, suggesting that folate intake during pregnancy plays an important role in the maintenance of myelin.


Assuntos
Encéfalo/metabolismo , Suplementos Nutricionais , Ácido Fólico/farmacologia , Lactação/metabolismo , Proteína Básica da Mielina/metabolismo , Gravidez/metabolismo , Medula Espinal/metabolismo , Animais , Antígenos Nucleares/efeitos dos fármacos , Antígenos Nucleares/metabolismo , Western Blotting/métodos , Encéfalo/efeitos dos fármacos , Córtex Cerebral/efeitos dos fármacos , Córtex Cerebral/metabolismo , Dieta/métodos , Feminino , Deficiência de Ácido Fólico/metabolismo , Lactação/efeitos dos fármacos , Modelos Animais , Proteína Básica da Mielina/efeitos dos fármacos , Proteínas da Mielina , Glicoproteína Associada a Mielina/efeitos dos fármacos , Glicoproteína Associada a Mielina/metabolismo , Glicoproteína Mielina-Oligodendrócito , Ratos , Ratos Sprague-Dawley , Medula Espinal/efeitos dos fármacos , Complexo Vitamínico B/farmacologia
10.
Obstet Gynecol ; 113(1): 142-151, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19104370

RESUMO

OBJECTIVE: To determine in fetal sheep the effect of betamethasone on myelination in relation to stage of myelination, number of treatment courses, dose, and route of administration. METHODS: Fetal expression of myelin basic protein (MBP), a marker of mature oligodendrocytes and myelin, was determined between 0.27 and 0.93 gestation. Short-term betamethasone effects were examined 24 hours after one maternal intramuscular treatment course (weight adjusted to equal the clinical dose of 2 x 8 mg betamethasone to a 70-kg woman) at 0.63, 0.75, and 0.87 gestation or after continuous 48-hour fetal intravenous infusion at 0.75 and 0.87 gestation. Lasting effects were examined 20 days after one and two treatment courses weight-adapted to the clinical dose of 2 x 8 mg or 2 x 12 mg betamethasone at 0.75 gestation. RESULTS: Myelin basic protein immunoreactivity was first detected in the internal capsule at 0.53 gestation, followed by the centrum semiovale, the superficial white matter, and corpus callosum at 0.63 gestation. Within 24 hours after treatment, betamethasone reduced the number of mature oligodendrocytes and MBP immunoreactivity. The effect decreased with gestational age. Maternal and fetal betamethasone administration had similar effects. Loss of MBP immunoreactivity was not reversed 20 days after two treatment courses, independent of dose. CONCLUSION: Betamethasone-induced delayed cerebral myelination is dependent on the stage of brain development in sheep. Betamethasone-related disturbances in myelination and any potential contribution to childhood behavior deficits need to be confirmed in clinical studies.


Assuntos
Betametasona/toxicidade , Encéfalo/embriologia , Feto/efeitos dos fármacos , Glucocorticoides/toxicidade , Bainha de Mielina/efeitos dos fármacos , Animais , Betametasona/administração & dosagem , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Encéfalo/fisiologia , Corpo Caloso/efeitos dos fármacos , Corpo Caloso/embriologia , Corpo Caloso/fisiologia , Feminino , Sangue Fetal/química , Glucocorticoides/administração & dosagem , Proteína Básica da Mielina/efeitos dos fármacos , Proteína Básica da Mielina/metabolismo , Bainha de Mielina/fisiologia , Oligodendroglia/efeitos dos fármacos , Oligodendroglia/fisiologia , Gravidez , Carneiro Doméstico
11.
Neuroimmunomodulation ; 15(1): 76-83, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18667803

RESUMO

OBJECTIVES: Based on evidence that pregnant women with multiple sclerosis (MS) show a decline in the relapse rate during the third trimester and an increase during the first 3 months postpartum, the suggestion was made that high levels of circulating sex steroids are responsible for pregnancy-mediated neuroprotection. As both estradiol (E(2)) and progesterone exert neuroprotective and myelinating effects on the nervous system, the effects of sex steroids were studied in the experimental autoimmune encephalomyelitis (EAE) model of MS. METHODS: EAE was induced in female C57BL/6 mice by administration of a myelin oligodendrocyte protein (MOG(40-45)) peptide. Clinical signs of EAE, myelin protein expression and neuronal parameters were determined in mice with or without hormonal treatment. RESULTS: Progesterone given prior to EAE induction attenuated the clinical scores of the disease, slightly delayed disease onset and decreased demyelination foci, according to luxol fast blue staining (LFB), myelin basic protein (MBP) and proteolipid protein (PLP) and mRNA expression. Motoneuron expression of Na,K-ATPase mRNA was also enhanced by progesterone. In turn, combined E(2) plus progesterone therapy more effectively prevented neurological deficits, fully restored LFB staining, MBP and PLP immunoreactivity and avoided inflammatory cell infiltration. On the neuronal side, steroid biotherapy increased brain-derived neurotrophic factor (BDNF) mRNA. CONCLUSION: Early treatment with progesterone alone or more evidently in combination with E(2) showed a clinical benefit and produced myelinating and neuroprotective effects in mice with MOG(40-45)-induced EAE. Therefore, sex steroids should be considered as potential novel therapeutic strategies for MS.


Assuntos
Encefalomielite Autoimune Experimental/tratamento farmacológico , Estradiol/farmacologia , Esclerose Múltipla/tratamento farmacológico , Sistemas Neurossecretores/imunologia , Progesterona/farmacologia , Animais , Fator Neurotrófico Derivado do Encéfalo/genética , Sistema Nervoso Central/efeitos dos fármacos , Sistema Nervoso Central/patologia , Sistema Nervoso Central/fisiopatologia , Modelos Animais de Doenças , Sinergismo Farmacológico , Quimioterapia Combinada , Encefalomielite Autoimune Experimental/imunologia , Encefalomielite Autoimune Experimental/fisiopatologia , Estradiol/metabolismo , Estradiol/uso terapêutico , Feminino , Humanos , Camundongos , Camundongos Endogâmicos C57BL , Esclerose Múltipla/imunologia , Esclerose Múltipla/fisiopatologia , Proteína Básica da Mielina/efeitos dos fármacos , Proteína Básica da Mielina/genética , Proteína Básica da Mielina/metabolismo , Proteína Proteolipídica de Mielina/efeitos dos fármacos , Proteína Proteolipídica de Mielina/genética , Proteína Proteolipídica de Mielina/metabolismo , Fibras Nervosas Mielinizadas/efeitos dos fármacos , Fibras Nervosas Mielinizadas/metabolismo , Fibras Nervosas Mielinizadas/patologia , Progesterona/metabolismo , Progesterona/uso terapêutico , RNA Mensageiro/efeitos dos fármacos , RNA Mensageiro/metabolismo , ATPase Trocadora de Sódio-Potássio/genética , Resultado do Tratamento , Regulação para Cima/efeitos dos fármacos , Regulação para Cima/fisiologia
12.
J Neurosci Res ; 86(16): 3536-47, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18683243

RESUMO

Our previous study showed that treatment with alpha-phenyl-n-tert-butyl-nitrone (PBN) after exposure to lipopolysaccharide (LPS) reduced LPS-induced white matter injury in the neonatal rat brain. The object of the current study was to further examine whether PBN has long-lasting protective effects and ameliorates LPS-induced neurological dysfunction. Intracerebral (i.c.) injection of LPS (1 mg/kg) was performed in postnatal day (P) 5 Sprague Dawley rat pups and PBN (100 mg/kg) or saline was administered intraperitoneally 5 min after LPS injection. The control rats were injected (i.c.) with sterile saline. Neurobehavioral tests were carried out from P3 to P21, and brain injury was examined after these tests. LPS exposure resulted in severe brain damage, including enlargement of ventricles bilaterally, loss of mature oligodendrocytes, impaired myelination as indicated by the decrease in myelin basic protein immunostaining, and alterations in dendritic processes in the cortical gray matter of the parietal cortex. Electron microscopic examination showed that LPS exposure caused impaired myelination as indicated by the disintegrated myelin sheaths in the juvenile rat brain. LPS administration also significantly affected neurobehavioral functions such as performance in righting reflex, wire hanging maneuver, cliff avoidance, negative geotaxis, vibrissa-elicited forelimb-placing test, beam walking, and gait test. Treatment with PBN, a free radical scavenger and antioxidant, provided protection against LPS-induced brain injury and associated neurological dysfunction in juvenile rats, suggesting that antioxidation might be an effective approach for therapeutic treatment of neonatal brain injury induced by infection/inflammation.


Assuntos
Dano Encefálico Crônico/tratamento farmacológico , Infecções Bacterianas do Sistema Nervoso Central/transmissão , Óxidos N-Cíclicos/uso terapêutico , Transmissão Vertical de Doenças Infecciosas , Leucomalácia Periventricular/tratamento farmacológico , Fármacos Neuroprotetores/uso terapêutico , Animais , Animais Recém-Nascidos , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Encéfalo/fisiopatologia , Dano Encefálico Crônico/induzido quimicamente , Dano Encefálico Crônico/microbiologia , Infecções Bacterianas do Sistema Nervoso Central/microbiologia , Infecções Bacterianas do Sistema Nervoso Central/fisiopatologia , Modelos Animais de Doenças , Feminino , Transtornos Neurológicos da Marcha/induzido quimicamente , Transtornos Neurológicos da Marcha/tratamento farmacológico , Transtornos Neurológicos da Marcha/microbiologia , Humanos , Recém-Nascido , Leucomalácia Periventricular/microbiologia , Lipopolissacarídeos/toxicidade , Masculino , Transtornos dos Movimentos/tratamento farmacológico , Transtornos dos Movimentos/microbiologia , Transtornos dos Movimentos/fisiopatologia , Proteína Básica da Mielina/efeitos dos fármacos , Proteína Básica da Mielina/metabolismo , Fibras Nervosas Mielinizadas/efeitos dos fármacos , Fibras Nervosas Mielinizadas/metabolismo , Fibras Nervosas Mielinizadas/patologia , Oligodendroglia/efeitos dos fármacos , Oligodendroglia/metabolismo , Oligodendroglia/patologia , Gravidez , Ratos , Ratos Sprague-Dawley , Recuperação de Função Fisiológica/efeitos dos fármacos , Recuperação de Função Fisiológica/fisiologia , Reflexo/efeitos dos fármacos , Reflexo/fisiologia
13.
J Neuroimmunol ; 190(1-2): 139-45, 2007 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17765980

RESUMO

Multiple sclerosis (MS) is a devastating autoimmune demyelinating disease of the central nervous system (CNS). This study investigated whether expression and activity of the calcium-activated protease calpain correlated with Th1/Th2 dysregulation in MS patients during states of relapse and remission. Calpain expression and activity were significantly increased in peripheral blood mononuclear cells (PBMCs) from MS patients, compared to controls, with the highest expression and activity noted during relapse. Th1 cytokines were highest and Th2 cytokines were lowest in MS patients during relapse. Treatment with calpain inhibitor, calpeptin, decreased Th1 cytokines in PBMCs from MS patients. Calpain inhibitor also reduced degradation of myelin basic protein (MBP) by inhibiting the calpain secreted from MBP-specific T cells. Taken together, these results suggested calpain involvement in Th1/Th2 dysregulation in MS patients.


Assuntos
Calpaína/imunologia , Citocinas/imunologia , Esclerose Múltipla/imunologia , Neutrófilos/imunologia , Células Th1/imunologia , Biomarcadores/análise , Biomarcadores/sangue , Cálcio/metabolismo , Sinalização do Cálcio/imunologia , Calpaína/antagonistas & inibidores , Calpaína/sangue , Citocinas/sangue , Dipeptídeos/farmacologia , Inibidores Enzimáticos/farmacologia , Feminino , Humanos , Masculino , Esclerose Múltipla/sangue , Esclerose Múltipla/fisiopatologia , Proteína Básica da Mielina/efeitos dos fármacos , Proteína Básica da Mielina/imunologia , Recidiva , Células Th1/metabolismo , Células Th2/imunologia , Células Th2/metabolismo , Regulação para Cima/imunologia
14.
J Neuroimmunol ; 190(1-2): 8-17, 2007 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17714795

RESUMO

Clusterin is a protein involved in multiple biological events, including neuronal cytoprotection, membrane recycling and regulation of complement-mediated membrane attack after injury. We investigated the effect of recombinant human clusterin in preclinical models of peripheral neuropathies. Daily treatment with clusterin accelerated the recovery of nerve motor evoked potential parameters after sciatic nerve injury. Prophylactic or therapeutic treatment of experimental autoimmune neuritis rats with clusterin also accelerated the rate of recovery from the disease, associated with remyelination of demyelinated nerve fibers. These data demonstrate that clusterin is capable of ameliorating clinical, neurophysiological and pathological signs in models of peripheral neuropathies.


Assuntos
Clusterina/farmacologia , Fatores de Crescimento Neural/farmacologia , Regeneração Nervosa/efeitos dos fármacos , Nervos Periféricos/efeitos dos fármacos , Doenças do Sistema Nervoso Periférico/tratamento farmacológico , Animais , Clusterina/imunologia , Clusterina/uso terapêutico , Citocinas/efeitos dos fármacos , Citocinas/imunologia , Citocinas/metabolismo , Modelos Animais de Doenças , Encefalomielite Autoimune Experimental/tratamento farmacológico , Encefalomielite Autoimune Experimental/imunologia , Encefalomielite Autoimune Experimental/fisiopatologia , Feminino , Hipocampo/imunologia , Hipocampo/metabolismo , Hipocampo/patologia , Camundongos , Camundongos Endogâmicos C57BL , Proteína Básica da Mielina/efeitos dos fármacos , Proteína Básica da Mielina/imunologia , Proteína Básica da Mielina/metabolismo , Bainha de Mielina/efeitos dos fármacos , Bainha de Mielina/imunologia , Bainha de Mielina/patologia , Fatores de Crescimento Neural/imunologia , Fatores de Crescimento Neural/uso terapêutico , Regeneração Nervosa/imunologia , Neurônios/efeitos dos fármacos , Neurônios/imunologia , Neurônios/patologia , Técnicas de Cultura de Órgãos , Nervos Periféricos/imunologia , Nervos Periféricos/fisiopatologia , Doenças do Sistema Nervoso Periférico/imunologia , Doenças do Sistema Nervoso Periférico/fisiopatologia , Proteínas Recombinantes/imunologia , Proteínas Recombinantes/farmacologia , Proteínas Recombinantes/uso terapêutico , Neuropatia Ciática/tratamento farmacológico , Neuropatia Ciática/imunologia , Neuropatia Ciática/fisiopatologia , Resultado do Tratamento
15.
Brain Res ; 1164: 14-23, 2007 Aug 20.
Artigo em Inglês | MEDLINE | ID: mdl-17644074

RESUMO

Periventricular leukomalacia (PVL), the dominant form of brain injury in premature infants, is characterized by white matter injury (WMI) and is associated with cerebral palsy. The pathogenesis of PVL is complex and likely involves ischemia/reperfusion, free radical formation, excitotoxicity, impaired regulation of cerebral blood flow, a procoagulant state, and inflammatory mechanisms associated with maternal and/or fetal infection. Using an established animal model of human PVL, we investigated whether activated protein C (APC), an anti-coagulant factor with anti-inflammatory, anti-apoptotic, anti-oxidant, and cytoprotective activities, could reduce endotoxin-induced WMI in the developing rat brain. Intraperitoneal injections of lipopolysaccharide (LPS) (0.5 mg/kg body weight) were given at embryonic days 18 (E18) and 19 (E19) to pregnant Sprague-Dawley rats; control rats were injected with sterile saline. A single intravenous injection of recombinant human (rh) APC (0.2 mg /kg body weight) was given to pregnant rats following the second LPS dose on embryonic day 19 (E19). Reduced cell death in white matter and hypomyelination were shown on TUNEL and myelin basic protein (MBP) staining, respectively, on late postnatal days (P7) in APC-treated groups. There were significantly fewer TUNEL+nuclei in the periventricular WM in the APC+LPS group than in the untreated LPS group. Compared to the APC+LPS and control group, MBP expression was weak in the LPS group on P7, indicating endotoxin-induced hypomyelination in the developing rat brain. APC attenuated the LPS-induced protein expression of inflammatory cytokines, tumor necrosis factor-alpha, and interleukin-6, as evaluated by ELISA in neonatal rat brains. A single intraperitoneal injection of rhAPC (0.2 mg/kg body weight) to neonatal rats on P1 also had similar protective and anti-inflammatory effects against maternally administered LPS. Collectively, these data support the hypothesis that APC may provide protection against an endotoxin-evoked inflammatory response and WMI in the developing rat brain. Moreover, our results suggest that the possible use of APC in treatment of preterm infants and pregnant women with maternal or placental infection may minimize the risk of PVL and cerebral palsy.


Assuntos
Encéfalo/efeitos dos fármacos , Encefalite/tratamento farmacológico , Endotoxinas/antagonistas & inibidores , Leucomalácia Periventricular/tratamento farmacológico , Fibras Nervosas Mielinizadas/efeitos dos fármacos , Proteína C/farmacologia , Animais , Animais Recém-Nascidos , Anticoagulantes/metabolismo , Anticoagulantes/farmacologia , Anticoagulantes/uso terapêutico , Apoptose/efeitos dos fármacos , Apoptose/fisiologia , Encéfalo/crescimento & desenvolvimento , Encéfalo/fisiopatologia , Infecções Bacterianas do Sistema Nervoso Central/complicações , Infecções Bacterianas do Sistema Nervoso Central/fisiopatologia , Paralisia Cerebral/etiologia , Paralisia Cerebral/fisiopatologia , Paralisia Cerebral/prevenção & controle , Modelos Animais de Doenças , Encefalite/complicações , Encefalite/microbiologia , Endotoxinas/toxicidade , Feminino , Humanos , Recém-Nascido , Mediadores da Inflamação/antagonistas & inibidores , Mediadores da Inflamação/metabolismo , Injeções Intravenosas , Leucomalácia Periventricular/fisiopatologia , Leucomalácia Periventricular/prevenção & controle , Lipopolissacarídeos/farmacologia , Proteína Básica da Mielina/efeitos dos fármacos , Proteína Básica da Mielina/metabolismo , Fibras Nervosas Mielinizadas/imunologia , Fibras Nervosas Mielinizadas/patologia , Fármacos Neuroprotetores/metabolismo , Fármacos Neuroprotetores/farmacologia , Fármacos Neuroprotetores/uso terapêutico , Gravidez , Proteína C/metabolismo , Proteína C/uso terapêutico , Ratos , Ratos Sprague-Dawley , Proteínas Recombinantes/farmacologia , Proteínas Recombinantes/uso terapêutico
16.
Eur J Neurosci ; 24(11): 3163-73, 2006 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17156377

RESUMO

Dithiocarbamates (DTCs), such as disulfiram, have been used in aversion therapy for alcoholism even though an inherent toxicity is induced, which is related mainly to peripheral neuropathy and is associated with behavioural and neurological complications. At anatomical and histopathological levels, DTCs affect structural elements in nervous tissue, such as axonal degeneration and alterations in the cytoskeletal proteins of astrocytes. Therefore, given the axonal effects of DTCs and to gain further insight into axonal growth and axonal pathfinding in the central nervous system (CNS), here we established an in vivo experimental model of mouse development. Daily intraperitoneal injections of N,N-diethyldithiocarbamate (DEDTC), the first metabolite of disulfiram, were given from postnatal day 2 (P2) until P15. From P16 until P30, animals were not treated. Treatment induced considerable physiological alterations, such as growth delay, throughout postnatal development. Moreover, by immunohistochemistry techniques, we observed important alterations in the cytoskeletal glial protein at early stages of postnatal development. At later stages (P15), the immunoreactivity pattern detected by an antibody against axonal neurofilaments (anti-NF-H) showed alteration in the axonal distribution pattern followed by drastic axonal loss at P22, data that were corroborated using an anti-MBP (myelin basic protein) antibody. Using an antibody against the beta amyloid precursor protein (APP), we detected axonal injury. Furthermore, given that we observed axonal re-growth in adulthood in the in vivo model presented, we propose that this model would be a good system in which to identify new strategies for inducing regenerative growth in neural diseases in which axonal regeneration is blocked.


Assuntos
Axônios/efeitos dos fármacos , Sistema Nervoso Central/efeitos dos fármacos , Sistema Nervoso Central/crescimento & desenvolvimento , Ditiocarb/análogos & derivados , Degeneração Neural/induzido quimicamente , Regeneração Nervosa/efeitos dos fármacos , Envelhecimento/fisiologia , Precursor de Proteína beta-Amiloide/efeitos dos fármacos , Precursor de Proteína beta-Amiloide/metabolismo , Animais , Animais Recém-Nascidos , Antídotos/toxicidade , Axônios/metabolismo , Axônios/patologia , Diferenciação Celular/efeitos dos fármacos , Diferenciação Celular/fisiologia , Sistema Nervoso Central/fisiopatologia , Proteínas do Citoesqueleto/efeitos dos fármacos , Proteínas do Citoesqueleto/metabolismo , Modelos Animais de Doenças , Ditiocarb/toxicidade , Cones de Crescimento/efeitos dos fármacos , Cones de Crescimento/metabolismo , Cones de Crescimento/patologia , Imuno-Histoquímica , Camundongos , Proteína Básica da Mielina/efeitos dos fármacos , Proteína Básica da Mielina/metabolismo , Degeneração Neural/patologia , Degeneração Neural/fisiopatologia , Regeneração Nervosa/fisiologia , Proteínas de Neurofilamentos/efeitos dos fármacos , Proteínas de Neurofilamentos/metabolismo , Neurotoxinas/toxicidade , Degeneração Walleriana/induzido quimicamente , Degeneração Walleriana/patologia , Degeneração Walleriana/fisiopatologia
17.
Brain Res ; 1117(1): 80-91, 2006 Oct 30.
Artigo em Inglês | MEDLINE | ID: mdl-17010319

RESUMO

In this work, we have immunohistochemically analyzed the effects of single injections of apotransferrin (aTf) on the expression of myelin (myelin basic proteins [MBPs]) and axonal (protein gene product 9.5 [PGP 9.5] and beta(III)-tubulin [beta(III)-tub]) proteins in colchicine-injected and crushed sciatic nerves of adult rats. A protein redistribution was seen in the distal stump of injured nerves, with the appearance of MBP- and PGP 9.5-immunoreactive (IR) clusters which occurred earlier in crushed nerves (3 days post-injury [PI]) as compared to colchicine-injected nerves (7 days PI). beta(III)-tub-IR clusters appeared at 1 day PI preceding the PGP 9.5- and MBP-IR clusters in colchicine-injected nerves. With image analysis, the peak of clustering formation was found at 14 days PI for MBP and at 3 days PI for beta(III)-tub in colchicine-injected nerves. At 28 days of survival, the protein distribution patterns were almost normal. The intraneural application of aTf, at different concentrations (0.0005 mg/ml, 0.005 mg/ml, 0.05 mg/ml, 0.5 mg/ml), prevented nerve degeneration produced by colchicine, with the appearance of only a small number of MBP- and beta(III)-tub-IR clusters. However, aTf was not able to prevent clustering formation when the nerve was crushed, a kind of injury that also involves necrosis and blood flow alterations. The results suggest that aTf could prevent the colchicine effects by stabilizing the cytoskeleton proteins of the nerve fibers, avoiding the disruption of the axonal transport and thus the myelin degeneration. Transferrin is proposed as a complementary therapeutic avenue for treatment of cytotoxic nerve injuries.


Assuntos
Apoproteínas/farmacologia , Axônios/efeitos dos fármacos , Proteínas do Tecido Nervoso/efeitos dos fármacos , Neuropatia Ciática/tratamento farmacológico , Transferrina/farmacologia , Degeneração Walleriana/tratamento farmacológico , Degeneração Walleriana/prevenção & controle , Animais , Transporte Axonal/efeitos dos fármacos , Transporte Axonal/fisiologia , Axônios/metabolismo , Colchicina/antagonistas & inibidores , Colchicina/toxicidade , Citoesqueleto/efeitos dos fármacos , Citoesqueleto/metabolismo , Citoesqueleto/patologia , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Imuno-Histoquímica , Microtúbulos/efeitos dos fármacos , Microtúbulos/metabolismo , Microtúbulos/patologia , Proteína Básica da Mielina/efeitos dos fármacos , Proteína Básica da Mielina/metabolismo , Bainha de Mielina/efeitos dos fármacos , Bainha de Mielina/metabolismo , Bainha de Mielina/patologia , Proteínas do Tecido Nervoso/metabolismo , Fármacos Neuroprotetores/farmacologia , Neurotoxinas/antagonistas & inibidores , Neurotoxinas/toxicidade , Ratos , Ratos Wistar , Neuropatia Ciática/metabolismo , Neuropatia Ciática/fisiopatologia , Resultado do Tratamento , Tubulina (Proteína)/efeitos dos fármacos , Tubulina (Proteína)/metabolismo , Ubiquitina Tiolesterase/efeitos dos fármacos , Ubiquitina Tiolesterase/metabolismo , Degeneração Walleriana/fisiopatologia
18.
Immunol Lett ; 103(1): 75-81, 2006 Feb 28.
Artigo em Inglês | MEDLINE | ID: mdl-16310860

RESUMO

Homogeneous IgG fractions were obtained by chromatography of the sera of patients with multiple sclerosis (MS) on Protein G-Sepharose under conditions that remove non-specifically bound proteins. These IgGs contained several chelated metals, the relative amount of which decreases in the order: Fe>or=Ca>Cu>or=Zn>or=Mg>or=Mn>or=Pb>or=Co>or=Ni. In contrast to homogeneous IgGs of healthy individuals, Abs of MS patients effectively hydrolyzed human myelin basic protein (MBP). A minor metal-dependent fraction was obtained by chromatography of highly purified IgGs from MS patient on Chelex-100. This IgG fraction did not hydrolyze human MBP in the absence of Me(2+) ions but was activated after addition of Me(2+) ions: Mg(2+)>Mn(2+)>Cu(2+)>Ca(2+). Proteolytic activities of IgGs from other MS patients were also activated by other metal ions (Ni(2+), Fe(2+), Co(2+), Zn(2+), Pb(2+), and Co(2+)) and especially Ni(2+). Ni(2+)-activated IgGs were separated into distinct MBP-hydrolyzing fractions by chromatography on HiTraptrade mark Chelating Sepharose charged with Ni(2+). Detection of Mg(2+)-dependent proteolytic activity in the SDS-PAGE area corresponding only to IgG provided direct evidence that IgG from sera of MS patients possesses metal-dependent human MBP-hydrolyzing activity. Observed properties of MS abzymes distinguish them from other known mammalian metalloproteases and demonstrate their pronounced catalytic diversity. Metal-dependent IgGs from MS patients represent the first example of abzymes with metal-dependent proteolytic activity.


Assuntos
Anticorpos Catalíticos/metabolismo , Metais Alcalinoterrosos/farmacologia , Metais Pesados/farmacologia , Esclerose Múltipla/imunologia , Proteína Básica da Mielina/metabolismo , Adolescente , Adulto , Anticorpos Catalíticos/farmacologia , Feminino , Humanos , Hidrólise , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla/sangue , Proteína Básica da Mielina/química , Proteína Básica da Mielina/efeitos dos fármacos
19.
Mol Cell Neurosci ; 31(3): 387-98, 2006 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16325417

RESUMO

Neurosphere cells (NSc) derived from embryonic stem cells have characteristics of neural stem cells and can differentiate into oligodendrocyte precursors. Culture of NSc with IL6RIL6 chimera (soluble interleukin-6 receptor fused to interleukin-6) enhances their differentiation into oligodendrocytes with longer and more numerous branches and with peripheral accumulation of myelin basic protein (MBP) in myelin membranes indicating maturation. Gene expression profiling reveals that one of the proteins strongly induced by IL6RIL6 is a regulator of microtubule dynamics, stathmin-like 2 (SCG10/Stmn2), and gene silencing shows that Stmn2 plays an important role in the development of the mature oligodendrocyte morphology. IL6RIL6 acts as an effective stimulator of the myelinating function of ES cell-derived oligodendrocyte precursors, as observed upon transplantation of the IL6RIL6- pretreated cells into brain slices of MBP-deficient shiverer mice.


Assuntos
Diferenciação Celular/fisiologia , Interleucina-6/metabolismo , Bainha de Mielina/metabolismo , Oligodendroglia/metabolismo , Receptores de Interleucina-6/metabolismo , Células-Tronco/metabolismo , Animais , Proteínas de Ligação ao Cálcio , Técnicas de Cultura de Células/métodos , Diferenciação Celular/efeitos dos fármacos , Linhagem Celular , Forma Celular/efeitos dos fármacos , Forma Celular/fisiologia , Regulação para Baixo/fisiologia , Interleucina-6/genética , Interleucina-6/farmacologia , Peptídeos e Proteínas de Sinalização Intracelular , Camundongos , Camundongos Mutantes Neurológicos , Dados de Sequência Molecular , Proteína Básica da Mielina/efeitos dos fármacos , Proteína Básica da Mielina/genética , Proteína Básica da Mielina/metabolismo , Bainha de Mielina/efeitos dos fármacos , Fatores de Crescimento Neural/efeitos dos fármacos , Fatores de Crescimento Neural/genética , Fatores de Crescimento Neural/metabolismo , Regeneração Nervosa/efeitos dos fármacos , Regeneração Nervosa/fisiologia , Oligodendroglia/efeitos dos fármacos , Técnicas de Cultura de Órgãos , Receptores de Interleucina-6/genética , Proteínas Recombinantes de Fusão/farmacologia , Estatmina , Transplante de Células-Tronco/métodos , Células-Tronco/efeitos dos fármacos , Regulação para Cima/efeitos dos fármacos , Regulação para Cima/fisiologia
20.
Toxicol Appl Pharmacol ; 213(2): 152-9, 2006 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-16325878

RESUMO

The goal of this investigation was to determine whether exposure to hyperbaric oxygen (HBO(2)) would ameliorate biochemical and functional brain abnormalities in an animal model of carbon monoxide (CO) poisoning. In this model, CO-mediated oxidative stress causes chemical alterations in myelin basic protein (MBP), which initiates an adaptive immunological response that leads to a functional deficit. CO-exposed rats do not show improvements in task performance in a radial maze. We found that HBO(2) given after CO poisoning will prevent this deficit, but not eliminate all of the CO-mediated biochemical alterations in MBP. MBP from HBO(2) treated CO-exposed rats is recognized normally by a battery of antibodies, but exhibits an abnormal charge pattern. Lymphocytes from HBO(2)-treated and control rats do not become activated when incubated with MBP, immunohistological evidence of microglial activation is not apparent, and functional deficits did not occur, unlike untreated CO-exposed rats. The results indicate that HBO(2) prevents immune-mediated delayed neurological dysfunction following CO poisoning.


Assuntos
Encéfalo/imunologia , Intoxicação por Monóxido de Carbono/imunologia , Doenças do Sistema Nervoso Central/imunologia , Oxigenoterapia Hiperbárica , Neurônios/imunologia , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Intoxicação por Monóxido de Carbono/complicações , Intoxicação por Monóxido de Carbono/terapia , Doenças do Sistema Nervoso Central/induzido quimicamente , Doenças do Sistema Nervoso Central/patologia , Modelos Animais de Doenças , Masculino , Aprendizagem em Labirinto/efeitos dos fármacos , Aprendizagem em Labirinto/fisiologia , Proteína Básica da Mielina/efeitos dos fármacos , Proteína Básica da Mielina/imunologia , Neurônios/efeitos dos fármacos , Neurônios/patologia , Estresse Oxidativo/efeitos dos fármacos , Estresse Oxidativo/fisiologia , Oxigênio/uso terapêutico , Ratos , Ratos Wistar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA